• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Right Arrow Button IconLeft Arrow Button IconHome
Right Arrow Button IconOzempic

Ozempic

Page 3 of 9
Novo Nordisk advertising flags and logo on facade, Danish pharmaceutical healthcare giant Novo Nordisk AS, production innovative drugs, obesity treatment Ozempic, Mainz, Germany June 15, 2024
HealthNovo Nordisk faces stock market bloodbath after weight-loss drug trial disappoints
By Ryan Hogg and AFPDecember 20, 2024
Merck snags Chinese obesity drug in nearly $2 billion deal
TechMerck snags Chinese obesity drug in nearly $2 billion deal
By Robert Langreth and BloombergDecember 18, 2024
Novo Nordisk invests $1.2 billion in new Danish factory to expand beyond insulin and weight-loss
TechNovo Nordisk invests $1.2 billion in new Danish factory to expand beyond insulin and weight-loss
By AFPDecember 16, 2024
Close-up of a patient administering a dose of Zepbound (tirzepatide)
HealthZepbound vs. Wegovy: New clinical trial says this weight-loss medication sheds more pounds
By Lindsey LeakeDecember 4, 2024
Ozempic box and medication
HealthOzempic covered by Medicare? It could be if Trump agrees to a Biden proposal with a $35 billion price tag
By The Associated PressNovember 26, 2024
Mads Krogsgaard Thomsen, chief executive officer of Novo Nordisk Foundation, during a panel session on day two of the World Economic Forum (WEF) in Davos, Switzerland, on Tuesday, May 24, 2022.
HealthNovo Nordisk Foundation CEO dismisses ‘Nokia risk’ as ‘fundamentally different’ for Denmark’s economy
By Ryan HoggNovember 26, 2024
Biden proposes Medicare and Medicaid cover weight-loss drugs like Wegovy and Ozempic for millions of obese Americans
HealthBiden proposes Medicare and Medicaid cover weight-loss drugs like Wegovy and Ozempic for millions of obese Americans
By Amanda Seitz and The Associated PressNovember 26, 2024
High demand for weight loss drugs like Ozempic and Wegovy is impacting employer health care costs—but it can be critical for retaining talent
LeadershipHigh demand for weight loss drugs like Ozempic and Wegovy is impacting employer health care costs—but it can be critical for retaining talent
By Brit MorseNovember 21, 2024
Novo Nordisk’s Wegovy sales jump on international rollouts
RetailNovo Nordisk’s Wegovy sales jump on international rollouts
By Naomi Kresge and BloombergNovember 6, 2024
A hand is seen holding Ozempic.
HealthNovo’s main Ozempic plant cited for quality lapses by FDA
By Madison Muller and BloombergOctober 29, 2024
Drugs like Ozempic and Wegovy are linked to a lower risk of Alzheimer’s disease, new study says
HealthDrugs like Ozempic and Wegovy are linked to a lower risk of Alzheimer’s disease, new study says
By Ani FreedmanOctober 24, 2024
Ozempic and Wegovy are trimming waistlines—and showing how quickly U.S. health care can turn into a gold rush
CommentaryOzempic and Wegovy are trimming waistlines—and showing how quickly U.S. health care can turn into a gold rush
By Owen TrippOctober 23, 2024
Unemployed Brits will receive free Ozempic-style weight-loss shots to help them get jobs
SuccessUnemployed Brits will receive free Ozempic-style weight-loss shots to help them get jobs
By Orianna Rosa RoyleOctober 17, 2024
Companies are more willing to consider covering weight-loss drugs
HealthCompanies are more willing to consider covering weight-loss drugs
By Chris MorrisOctober 10, 2024
Despite the ubiquitousness of injectable GLP-1 drugs indicated for people with obesity, most Americans wouldn’t take them, according to a September 2024 survey from the Physicians Committee for Responsible Medicine.
HealthMost Americans who want to lose weight don’t want to take GLP-1 drugs like Wegovy and Zepbound, new survey says
By Lindsey LeakeOctober 10, 2024
1
  • 1
  • 2
  • 3
  • 4
  • 5
...9
Most Popular
Success
Two-thirds of parents say their adult Gen Z kids still rely on them financially  for support—even though it's putting them under strainplaceholder alt text
By Fortune EditorsMarch 31, 2026
Economy
Jerome Powell says the $39 trillion national debt is ‘not unsustainable,’ but warns the trajectory ‘will not end well’placeholder alt text
By Fortune EditorsMarch 30, 2026
Personal Finance
Current price of gold as of April 1, 2026placeholder alt text
By Fortune EditorsApril 1, 2026
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.